XMT-2068

XMT-2068 is an immune-stimulating antibody-drug conjugate (ISAC) developed by Mersana Therapeutics. It is designed as a STING (Stimulator of Interferon Genes, also known as MPYS protein) agonist ADC that targets a tumor-associated antigen, with the goal of stimulating innate immune responses against cancer cells. The specific tumor antigen targeted by XMT-2068 has not been publicly disclosed. The drug leverages Mersana’s Immunosynthen platform to deliver targeted activation of the STING pathway within tumors, aiming to increase anti-tumor potency while minimizing systemic toxicity. As of the latest updates, XMT-2068 remains in preclinical development for cancer indications[1][2][3].